retatrutide trials in boston biotech secures Series A funding to move its once-weekly GLP-1 obesity patch into first-in-human clinical trials. ㅤ Link bio. ㅤ #longevity #obesity #glp1 #clinicaltrials #biotech Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Can I track GLP-1 side effects like nausea or constipation

Vilsbll has received personal honoraria for consulting, lectures and/or for advisory board participation within the last 36 months from Amgen, AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, and Zealand Pharma and has received unrestricted research grants from Novo Nordisk and the Novo Nordisk Foundation

You are learning how your body responds to the blend

But Eimer emphasized that the findings should not discourage appropriate use of GLP-1 drugs, which have become increasingly popular for treating diabetes, obesity, cardiovascular disease and sleep apnea